- Prescient Therapeutics (PTX) expands its clinical study of patients with relapsed and refractory acute myeloid leukaemia (AML)
- The addition to the company’s Phase 1b clinical study of PTX-200 and cytarabine follows another complete patient remission, bringing the total in this study to four
- Three additional patients will now be part of the study at the same dose level of 45 milligrams of the treatment
- Prescient Therapeutics climbs 28 per cent, trading at 16 cents
Prescient Therapeutics (PTX) is set to expand its clinical study of patients with relapsed and refractory acute myeloid leukemia.
Re-announced today as price sensitive, the company’s Phase 1b clinical study of PTX-200 and cytarabine will expand the cohort at 45 milligrams of PTX-200, following another complete remission and no dose limiting toxicities at this dose level.
Three patients have been treated at 45 milligrams PTX-200 together with cytarabine, with no dose limiting toxicities reported.
One patient in the cohort achieved a CRi, meaning complete remission of disease, with neutrophils and platelets yet to recover to normal levels. This latest patient brings the total of complete remissions in this study to four, while one patient in the prior cohort was determined to have a partial response.
“It is very satisfying to see another patient with remission in a disease that is so aggressive and fatal,” Prescient CEO and Managing Director Steven Yatomi-Clarke said.
“Despite recent advancements, AML remains a disease of unmet medical need, and we look forward to advancing this study with the aim of benefiting more AML patients.”
This latest data, together with data from the previous Phase 1 monotherapy study, guided the research team to expand enrolment at this dose level to another three patients, to further explore safety and efficacy at this dose level.
Prescient Therapeutics climbed 28 per cent, trading at 16 cents at market close.